C-Ray Therapeutics (Shanghai) Co., Ltd. Presents Breakthrough Clinical Data of Novel Targeted Alpha Therapy 225Ac-PSMA-CY313 at EANM 2025

BARCELONA, Spain, Oct. 8, 2025 /PRNewswire/ -- During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025), C-Ray Therapeutics (Shanghai) Co., Ltd. ("C-Ray Shanghai"), a company dedicated to the development of innovative targeted radiopharmaceuticals, announced promising new clinical results for its lead program ²²⁵Ac-PSMA-CY313 in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

These data, highlighted in two Top Rated Oral Presentations, provide early clinical evidence of the therapy's significant potential and favorable safety profile, marking an important milestone for C-Ray in the field of targeted alpha therapies. Both presentations were delivered by the company's Chief Medical Officer.

One presentation, entitled "Feasibility study of ²²⁵Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT", showcased the company's progress in dosimetry research with ²²⁵Ac. The study successfully established and validated a quantitative dosimetry approach using SPECT/CT to evaluate internal radiation doses in patients treated with ²²⁵Ac-PSMA-CY313. Findings demonstrated that tumors (particularly soft tissue lesions) received high absorbed doses, while key organs such as the kidneys and liver remained within safe exposure limits—supporting a favorable therapeutic window. Importantly, no severe adverse events (SAEs) or grade ≥3 toxicities were observed during treatment.

The second presentation, "Evaluation of the safety and efficacy of ²²⁵Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results", reported clinical outcomes from 13 patients treated with ²²⁵Ac-PSMA-CY313. The study results showed encouraging efficacy and manageable safety in heavily pretreated, standard therapy–resistant mCRPC patients. All patients (100%) achieved reductions in prostate-specific antigen (PSA) levels, with 81.8% achieving PSA50 response (≥50% decline). Among evaluable patients, the objective response rate (ORR) reached 60%. Most adverse events were grade 1–2, with the most common being xerostomia (dry mouth) reported in 11 of 13 patients (84.6%), including 10 grade 1 and 1 grade 2 events (per CTCAE v5.0 criteria).

"Presenting these results on such a globally recognized stage as EANM represents a significant milestone for C-Ray," said the Chief Medical Officer of C-Ray Shanghai. "There are only a few teams worldwide that have successfully advanced an alpha-emitting radiopharmaceutical into clinical development. Not only have we developed ²²⁵Ac-PSMA-CY313, but we have also generated robust early clinical data from more than a dozen patients. This underscores our strong capabilities and commitment in both radiopharmaceutical R&D and clinical translation."

About C-Ray Therapeutics (Shanghai) Co., Ltd.

C-Ray Therapeutics (Shanghai) is a biotechnology company focused on the discovery and development of innovative targeted radiopharmaceuticals. Based in Shanghai, the company is advancing its pipeline from early-stage discovery through clinical development, while building proprietary conjugation and linker platforms. C-Ray actively seeks global partnerships to accelerate innovation in ligands, linkers, and conjugation technologies.

To ensure seamless translation from early research through clinical development, C-Ray Shanghai works closely with its affiliated company, C-Ray Therapeutics (Chengdu) Co., Ltd. This strategic collaboration leverages C-Ray Chengdu's specialized CRDMO services, covering radiochemistry process development, quality research, preclinical evaluation, IND-enabling support, clinical supply, and commercial-scale manufacturing with secure logistics. This integrated model allows C-Ray Shanghai to remain focused on innovation and the expansion of its core competencies.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

C-Ray Therapeutics (Shanghai) Co., Ltd. Presents Breakthrough Clinical Data of Novel Targeted Alpha Therapy 225Ac-PSMA-CY313 at EANM 2025

Over 15,000 visitors to the INCHEON–IFEZ Booth; IFEZ supported a record 50 innovation companies participating in CES 2026.
Participating companies secure a foundation for global expansion, including 20 MoU signings.

INCHEON, South Korea, Jan. 16, 2026 /PRNewswire/ -- The Incheon Free Economic Zone (IFEZ) announced the successful operation of the INCHEON–IFEZ Booth at CES 2026, presenting IFEZ's future-city vision and the technologies of Incheon-based innovators to a global audience.

Under the theme "Destination Incheon — From Smart City to AI City," the booth highlighted a sustainable urban future enabled by Incheon companies' innovations and drew more than 15,000 visitors, according to IFEZ.

During CES 2026, IFEZ also met with the Fairfax County Economic Development Authority (FCEDA) to discuss support measures and collaboration models for helping Incheon startups enter the U.S. market. The two sides plan to develop practical joint programs through continued cooperation.

IFEZ supported a record 50 companies at CES 2026 across multiple participation tracks, dividing them across various exhibition areas: 10 companies in the 'INCHEON-IFEZ' Booth at the Las Vegas Convention Center, 10 in the Korea pavilion (KOTRA) at the Eureka Park, 6 in the Global Pavilion, and 15 as the Incheon Startup Park Delegation and 10 Innovation Award showcase participants.

These companies achieved record-breaking results, conducting 1,419 business consultations with overseas buyers and investors, with the estimated value of export consultations reaching $560 million—more than 400 additional meetings compared to last year. In addition, nine companies signed 20 MOUs, building momentum for global expansion and investment opportunities.

Leadpoint System, a smart manufacturing and industrial automation solutions provider, signed an MOU with Webtronic Labs, a U.S.-based technology R&D company.

emCT, which specializes in fire detection and safety management solutions, signed an MOU with Texas Legacy Realty, a Texas-based real estate development and operations company, to pursue collaboration on applying fire safety and "safe zone" solutions in commercial and residential buildings.

Medicell Healthcare, a regenerative medicine and bio-healthcare solutions company, signed an MOU with the City of Phoenix, Arizona's largest city, and discussed cooperation on technology collaboration and local proof-of-concept initiatives in public healthcare.

IFEZ said 14 supported companies earned 17 CES Innovation Awards, the highest total to date for Incheon, drawing strong interest from global buyers and investors. Deep Fusion AI received a Best of Innovation honor for its radar-based sensor-fusion AI technology, gaining attention in next-generation autonomous driving and robotic perception.

Mayor Yoo Jeong-bok said the CES participation advanced the Incheon–IFEZ AI City vision on the global stage and pledged continued support to expand Incheon companies' international reach and strengthen Incheon as a global business hub.

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

INCHEON-IFEZ Booth Wraps Up a Successful CES 2026, Recording $560M in Export Consultations and 17 Innovation Awards